Spectacular results and effectiveness at Zolgensma in early onset spinal muscular atrophy

Avexis/Novartis the company discloses new results of the gene replacement Therapy the intravenous AVXS-101 (Zolgensma).
The data showed from the US clinical called STR1VE

The application for approval for Zolgensma has already been submitted to the authorities (FDA, EMA and in Japan), of course based on the data. Decisions are expected in 2019.

Publisert av

Liz

Until those day, was my kiss of death been stronger than those of the devil. I like to ride through hellfire with him ,when I come out victorious afterwards. I'm strong and proud rheumatoid arthritis warrior Följ mig, tack! Liz - Fotoblogg Spelblogg

2 tankar om “Spectacular results and effectiveness at Zolgensma in early onset spinal muscular atrophy”

Innlegget er stengt for innspel.